The Best Non Comedogenic Makeup for a Full Beat, Sans Breakout
Celebrity makeup artist Andrea Ventura agrees. 'It's critical to avoid pore-clogging makeup especially if you have sensitive skin, oily skin, or acne-prone skin. For those with any of these skin types, using makeup with comedogenic ingredients ultimately traps bacteria and oil in pores, is clogging your pores, leading to more breakouts,' Ventura tells Vogue.
Vogue's Non-Comedogenic Makeup Picks
In This Story
Rather than cross my fingers whenever I try a new powder blush or foundation, I decided to take control. Call it my beauty bag reckoning—a spring clean guided by acne-safe ingredient lists, and comedogenicity ratings. Inspired by Pavitt's advice of avoiding all comedogenics while on a skin-clearing protocol, I took to scanning every label with the scrutiny of a chemist, purging anything that didn't pass the acne-safe test. 'Why risk it? Minimize the risk of pore-clogging from triggers, and your skin will clear faster,' Pavitt previously told Vogue, and the same concept can be applied to cosmetics.
One word of warning: while many brands claim their products are non-comedogenic, don't take the label at face value. I've made a habit (or perhaps, obsession) of pasting ingredient lists into Sofie Pavitt's pore-clogging checker—and let's just say it's exposed more than a few imposters. The result? A tighter, more intentional edit of color cosmetics. The clean-out focused strictly on complexion products—foundation, concealer, powders—while eyes, lips, and brows got a free pass as the lesser of acne-prone areas.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
26 minutes ago
- CNN
On GPS: The Trump administration's war on science
Secretary of Health and Human Services Robert F. Kennedy Jr. announced that he is cutting nearly half a billion dollars in federally funded mRNA vaccine research. Fareed speaks with former Baltimore Health Commissioner Dr. Leana Wen about the promises of mRNA technology for treating infectious diseases and the impact of cuts on America's scientists.
Wall Street Journal
26 minutes ago
- Wall Street Journal
A Trump-Biden Mind Meld on Price Controls
Photo: Eric Thayer/Bloomberg News Your editorial 'The Political Race for Fewer Cures' (Aug. 6) identifies an ironclad rule of economics: Price controls create shortages. In this instance, restrictions on prescription drugs will lead to fewer cures. But there's another unintended consequence: Price controls will push down rebate payments to health plans. Those payments by drug makers are linked to list price—the higher the price, the higher the rebate payment. The sums allow patients to more easily access prescription drugs through lower out-of-pocket costs and reduced paperwork for doctors. Yet when the government artificially pushes down prices, they reduce rebate payments to health plans and their pharmacy benefit managers.
Yahoo
an hour ago
- Yahoo
1 Beaten-Down Stock That Could Soar by the End of the Year
Key Points Viking's leading weight management candidate is being investigated in two formulations. The stock could soar later this year, provided the oral version aces phase 2 studies. Viking Therapeutics is somewhat risky, but it also has significant upside potential. 10 stocks we like better than Viking Therapeutics › Some smaller drugmakers choose to develop medicines for diseases for which there are no therapeutic options. This allows them to avoid direct competition from larger pharmaceutical companies. That's not exactly the strategy Viking Therapeutics (NASDAQ: VKTX) chose. The mid-cap biotech is working on weight loss therapies, an increasingly competitive market dominated by Eli Lilly (NYSE: LLY) and Novo Nordisk, as well as numerous other well-established players in the industry seeking to enter the space. Going up against these giants is no small challenge, but Viking is, so far, holding its own. And if it can play its cards right, its stock could soar by the end of the year and go on to generate strong returns from then on out. Here's more on Viking Therapeutics. Eli Lilly's setback creates an opportunity Viking Therapeutics' shares soared last year following the release of strong phase 2 data for its subcutaneous weight management candidate, VK2735. The stock has declined significantly since that milestone, although it's not due to anything Viking did wrong. Broader market volatility, combined with long-term shareholders taking some profits, is likely responsible for the stock's 40% drop over the trailing-12-month period. VK2735 is currently in phase 3 studies, but Viking is also developing an oral version of the medicine, which is in phase 2 clinical trials. There is a race to develop a highly effective oral GLP-1 anti-obesity therapy, since the current market leaders are administered via subcutaneous injection. If Viking Therapeutics' oral candidate can impress in mid-stage studies, the stock could soar. That's especially the case since Eli Lilly's investigational oral GLP-1 medicine, orforglipron, failed to perform as well as expected in a phase 3 study in obese or overweight patients who didn't have diabetes. Orforglipron led to a mean weight loss of 12.4% in a 72-week study, which wasn't as impressive as the market wanted. This result paled in comparison to Lilly's injectable Zepbound, which led to an average weight loss of 20.2% in a phase 3 study. Viking Therapeutics' shares jumped on the pharmaceutical giant's bad news, but there's plenty of upside left if its oral weight loss candidate meets Wall Street's expectations. It's best to start small Eli Lilly is perceived as the leader in the weight management market. The company's continued dominance in this field was likely somewhat baked into investor expectations, requiring it to deliver outstanding clinical trial results to justify its share price. Viking is a much smaller drugmaker than Lilly, so the market will likely have lower expectations for its data readouts for VK2735. Viking also has several other exciting candidates. The company is working on a drug called VK2809, a potential therapy for metabolic dysfunction-associated steatohepatitis (MASH), which produced solid results in phase 2 studies. There is a vast unmet need in MASH, considering several million people have the disease, yet the U.S. Food and Drug Administration has approved just a single medication for it. Elsewhere, Viking has a next-gen anti-obesity candidate that could soon start human clinical trials. The company has a lot going on, and if VK2735-related developments remain strong through the end of the year, the stock could soar. However, Viking -- like any clinical-stage biotech company -- is a somewhat risky bet. On the one hand, it has generated strong mid-stage data for two separate medicines that address high unmet needs. Its leading candidate, VK2735, has the potential to become a blockbuster; that's impressive. Even so, the stock will plummet if VK2735 encounters clinical setbacks. So, should you buy shares? In my view, it depends on your level of risk tolerance. Risk-averse investors should look elsewhere. If you're comfortable with a bit of volatility, you should seriously consider the stock; however, it would be wise to start by initiating a small position. If the data from the ongoing phase 2 study for oral VK2735 is good, it might be worth adding even more shares thereafter. Should you buy stock in Viking Therapeutics right now? Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Eli Lilly, Novo Nordisk, and Viking Therapeutics. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. 1 Beaten-Down Stock That Could Soar by the End of the Year was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
